The osteoinductive capability of BMPs appears diminished in the setting of acute infection. We applied rhBMP-2 to a segmental defect in a rat femur and measured the expression of key bone formation genes in the presence of acute infection. Types I and II collagen, osteocalcin, and BMP Type II receptor mRNA expression were characterized in 72 Sprague-Dawley rats, which received either bovine collagen carrier with 200 lg rhBMP-2 plus Staphylococcus aureus, carrier with bacteria only, carrier with rhBMP-2 only, or carrier alone. Six animals from each group were euthanized at 1, 2, and 4 weeks. Total RNA was isolated and extracted, and mRNA was determined by real-time comparative quantitative PCR. Infected defects had little expression of collagen I and II and osteocalcin mRNAs, while BMP receptor II expression with infection was greater than carrier-only controls at Weeks 2 and 4. Notably, all four genes were upregulated in infected defects in the presence of rhBMP-2. Thus, in a clinical setting with a high risk of infection and nonunion, such as a compound fracture with bone loss, rhBMP-2 may increase the rate and extent of bone formation. Even if infection does occur, rhBMP-2 may allow a quicker overall recovery time.
Introduction
Deep infection is one of the most difficult complications encountered after the surgical management of fractures. When infection occurs after internal fixation, further surgery is almost always required, and the infection threatens both fracture healing and retention of the associated implant. The presence of an orthopaedic implant complicates the treatment of osteomyelitis by serving as a site for bacterial glycocalyx formation [18] . Yet, it is clear maintaining fracture stability is important for obtaining fracture union and decreasing the clinical progression of infection [35] . The clinician therefore faces a difficult decision regarding the merits of implant removal versus maintaining fracture fixation.
Our previous research has shown BMP stimulates healing of a critical defect in the rat femur in the presence of both acute and chronic infection [4] [5] [6] [7] . Both fracture healing and the host response to infection involve complex temporal and spatial interactions among various cytokines and other cell-signaling molecules. Genetic mechanisms underlying the host response to infection at the site of a healing fracture are poorly understood, as are the changes in gene regulation potentially induced by growth factors.
Although there are numerous genes involved in the repair of noninfected and infected fractures, we focus on four due to the essential roles they play in different stages of endochondral ossification and bone defect healing [42] . Types I and II collagen are frequently used as markers of bone growth, osteocalcin reflects matrix mineralization [26] , and BMP Type II receptor was chosen to identify potential changes in expression due to the exogenous rhBMP-2 application [31] . By understanding how the regulation of genes involved in infected fracture healing is affected favorably by BMP application, we hope to clarify evidence for the use of BMPs in clinical settings where infection is likely.
We hypothesized rhBMP-2 addition in the setting of an acutely infected fracture would increase mRNA expression of the four selected genes relative to an infected defect without rhBMP-2. In addition, we hypothesized rhBMP-2 would accelerate the expression of bone formation genes in the setting of infection, as shown by an earlier peak in the level of gene expression at the time points of 1, 2, and 4 weeks.
Materials and Methods
A 6-mm mid-diaphyseal defect was surgically created under aseptic conditions and stabilized with a polyacetyl plate and six Kirschner wires in the left femur of 72 Sprague-Dawley rats (350-399 g) [4] . The animals were divided into four treatment groups of 18 animals ( Table 1 ). The first group received a 1-9 1-9 0.4-cm segment of Type I bovine collagen sponge (absorbable collagen sponge [ACS]; Medtronic Sofamor Danek, Memphis, TN) wetted with 0.1 mL sterile water containing 200 lg rhBMP-2 (Medtronic Sofamor Danek), which was allowed to bind to the ACS during a 15-minute soak period at room temperature. Then, 0.1 mL normal saline containing 5 9 10 5 colony-forming units (CFUs) of Staphylococcus aureus was added to the sponge, and the wetted sponge was packed into the defect. This group is referred to as the rhBMP-2/infection group. The second group received an ACS wetted with 0.1 mL sterile water alone (no rhBMP-2), followed 15 minutes later by addition of a 0.1-mL suspension of 5 9 10 5 CFUs of S aureus (infection group). Bacterial introduction at the time of fixation was chosen in an attempt to minimize confounding variables that may affect the gene expression profile and time course during fracture healing and to simulate a clinical scenario in which there is a higher probability of infection despite débridement (eg, open fractures or revision of infected internal fixation devices). The third group received an ACS with 200 lg rhBMP-2 in sterile water and normal saline without bacteria (rhBMP-2 group). The fourth group received an ACS wetted only with 0.1 mL sterile water and 0.1 mL normal saline (carrier-only group). The carrier-only and rhBMP-2 only conditions were included as controls to verify bone growth would occur without the presence of infection, as would be expected [55] . Six animals from each of the four groups were euthanized at 1, 2, or 4 weeks after surgery. The ACS is the commercially available inert carrier for rhBMP-2 with a previously characterized rhBMP-2 release pattern [5] and also served to retain the bacteria within the defect in the short term. The pathogenic isolate of S aureus used in this study was previously obtained from a patient with an infected THA and is penicillin sensitive. All procedures in this study were approved by our Institutional Animal Care and Use Committee.
A single surgeon (XC) performed all surgeries using a previously described procedure [4] . Animals were anesthetized with an intraperitoneal injection of ketamine (80-120 mg/kg) and xylazine (2-3 mg/kg). A lateral approach to the femur was performed, and muscles and periosteum were stripped from the diaphysis. A predrilled, six-hole polyacetyl plate (Midwest Orthopaedic Research Foundation, Minneapolis, MN) was fixed to the femur bicortically with 0.9-mm threaded Kirschner wires. A full-thickness 6mm defect was then created with a small pneumatic-powered oscillating saw. The collagen sponge and its contents were placed inside the defect and the wound was closed. An analgesic (buprenorphine, 0.013-0.026 mg/kg) was administered intramuscularly immediately after surgery. The animals were allowed full activity postoperatively, and their activity level, food intake, and surgical wound were monitored daily.
To minimize RNase activity before tissue procurement (which would confound our results), each rat was anesthetized and the femur exposed under sterile conditions and harvested in vivo. All animals with previously inoculated defects showed signs of a localized infection, which included a well-defined pus-filled fibrous membrane encasing the defect and fixation, and no apparent infection of the surrounding tissues. The fibrous membrane was isolated and opened in these animals; cultures were obtained and subsequently inoculated on plated media to verify bacterial growth. The femoral defect was exposed, and the new bone bridging the defect was removed for gene expression evaluation. Care was taken to exclude muscle tissue from the sample. After being harvested, the tissue sample was immediately placed in a vial and snap-frozen in liquid nitrogen. The animals were euthanized by an intraperitoneal barbiturate injection. Tissues obtained from the femoral defects were handled and processed for RNA isolation, cDNA synthesis, and real-time comparative quantitative PCR according to generally accepted techniques (Appendix 1). A three-way analysis of variance was used to determine the effect of the independent variable of rhBMP-2 (200 lg) in the setting of infection (5 9 10 5 CFUs) and also the effect of time (1, 2, and 4 weeks) on the dependent expression of each of the four genes (SigmaStat 1 ; Systat Software, Inc, San Jose, CA). Pairwise comparisons were made with the Student-Newman-Keuls method between the independent variable of rhBMP-2 treatment in the setting of infection and the dependent variable of mRNA expression of the four selected genes. Post hoc analysis was performed for each of the bone formation genes between the conditions of rhBMP-2 plus infection and infection alone at each of the three time points studied.
Results
Visual assessment of the newly mineralized callus at the time of harvest for RNA isolation revealed treatment with rhBMP-2 alone produced exuberant callus within and around the defect by 4 weeks, while defects filled with the collagen sponge alone exhibited minute amounts of callus formation at 2 and 4 weeks. This confirmed the efficacy of rhBMP-2 treatment in the absence of infection. The infected animals treated with rhBMP-2 also had extensive callus despite the obvious infection. In contrast, the infected animals without rhBMP-2 exhibited essentially no bone formation. Swab samples and subsequent bacterial cultures revealed all contaminated defects became infected. For the four treatment groups in this study, amplification efficiencies for all genes were similar, ranging from 97% to 100%. While b-actin expression increased slightly with infection when evaluated with BMP receptor II mRNA, the magnitude of change for the BMP receptor II gene was over twofold greater than that of b-actin. b-Actin expressed no interactions as the normalizer for the other three genes.
Overall, gene expression was greater in infected defects receiving rhBMP-2 than in infected defects without rhBMP-2 for all four genes. Although rhBMP-2 treatment did not reveal any difference in collagen I expression at 1 week ( Fig. 1) , addition of rhBMP-2 to an infected defect elicited greater (p = 0.010) collagen I mRNA expression at 2 and 4 weeks, compared with the carrier/infection group. Addition of rhBMP-2 to an infected defect resulted in greater collagen II expression at 2 weeks (p = 0.019) and 4 weeks (p \ 0.001), compared with the carrier/ infection group (Fig. 2) . Concurrently, peak osteocalcin expression in the rhBMP-2/infection group occurred at 4 weeks ( Fig. 3 ). Addition of rhBMP-2 to an infected defect resulted in greater osteocalcin message at 2 and 4 weeks (p = 0.002), compared with infection defects alone. Interestingly, animals with infected defects with and without rhBMP-2 exhibited a similar time course of BMP receptor II expression, while the two uninfected groups exhibited a different temporal pattern (Fig. 4) . Treatment of infected defects with rhBMP-2 increased BMP receptor II expression at Week 1 (p = 0.014), compared to defects with carrier/infection. Addition of bacteria to rhBMP-2-treated animals resulted in greater (p = 0.021) BMP receptor II expression at Week 2.
Peak gene expression occurred sooner in infected defects with rhBMP-2 than in infected defects without the growth factor only for the BMP Type II receptor gene. The peak occurred 2 weeks earlier ( Fig. 4 ). Gene expression of Type I collagen peaked at 2 weeks for both infection alone and rhBMP-2 with infection ( Fig. 1 ). Type II collagen achieved its highest level at 1 week for infection but reached its much higher peak at 2 weeks with rhBMP-2/ infection (Fig. 2) . While osteocalcin peaked at 2 weeks for the infection condition, it was at a very low level in comparison to the later peak at 4 weeks for the rhBMP-2/ infection condition (Fig. 3) .
Unexpectedly, expression of BMP receptor II mRNA was greater (p = 0.027) in animals with infection than without infection over all time points. This is in contrast to the other three genes where expression was greater in the uninfected conditions in comparison to the infected conditions. Another surprising finding was the greater Type I collagen expression in the uninfected carrier only condition versus rhBMP-2 treatment.
Discussion
Fracture healing proceeds through consistent spatial and temporal patterns regulated by complex relationships between the local fracture environment, vascularity [14] , growth factors [12] , cellular elements [19] , presence of internal fixation [51] , and infection [1, 13] . Many studies have demonstrated the ability of BMPs to promote fracture healing within a critical defect [10, 25, 53, 55] and to heal nonunions in humans [17] . In a series of previous animal studies, we used histology, biomechanical testing, radiography, and high-resolution CT to document BMPs promote healing of an infected critical defect and the amount of bone formed is also influenced by antibiotic therapy [4] [5] [6] [7] . For this study, we hypothesized the differing patterns of bone formation observed may be due to changes in levels of gene activation in response to BMP administration, modulated by the effects of the infection. Our first hypothesis examined whether rhBMP-2 would upregulate the expression of four genes (osteocalcin, Types I and II collagen, and BMP Type II receptor) associated with bone formation in the presence of an acute infection, in comparison to an infected defect not receiving rhBMP-2. To examine the hypothesis regarding the timing of changes in gene activation, mRNA expression of these genes was determined at 1, 2, and 4 weeks postfracture.
The major limitations of this study include the use of an animal model, an acute versus chronic infection, gene expression profiling of only four genes, and the fact that we did not directly measure bone formation in these same animals. We chose a well-defined animal model to have a repeatable, safe, in vivo environment in which to measure the effect of rhBMP-2 application [13] . We chose to use an acute infection without antibiotic therapy because such a model provided a more controlled infected environment than a chronic infection model [7] . The four genes studied have well-characterized temporal patterns of expression in noninfected defect healing [3, 37, 54] , which we believed would be helpful for comparison to rhBMP-2 application. Although we could have used a gene microarray to study many more genes, we chose to use PCR because it is a more targeted and quantitative approach to further characterize genes involved in callus formation. Finally, we were unable to measure bone growth directly or perform high-resolution imaging because the callus had to be harvested from the femoral defects in situ before the animal was euthanized and immediately snap-frozen in liquid nitrogen to prevent RNA degradation. However, since the experimental techniques and model used in this study are the same as used in our previous study [4] , we consider the differences in bone formation we previously observed are the result of the differences in gene activation shown in this study.
The results reported herein confirmed upregulation of all four genes in animals receiving rhBMP-2, most notably at 2 and 4 weeks. As expected, Type I collagen mRNA was highly expressed in all experimental conditions, indicating bone matrix formation [19, 42] . Application of rhBMP-2 to infected defects induced greater Type I collagen expression than the infected condition alone. Maximal expression of Type I collagen message at 2 weeks is consistent with previous research of de novo osteogenesis [42, 54] , fracture repair [26, 37] , and bone formation within a critical defect [47] . We expected carrier/rhBMP-2 treatment alone would elicit the greatest Type I collagen signal. However, carrier-only controls expressed greater message at 2 weeks. One possible explanation for this is that BMP accelerates remodeling wherein bone formation is preceded by bone resorption, consistent with an earlier reported observation [46] . Type II collagen message was also increased due to rhBMP-2 in the infected conditions, but its expression was generally at low levels and essentially nonexistent for all conditions by 4 weeks, consistent with endochondral ossification [16, 42] by chondrocytes and osteoblasts [45] . Compared to Type I collagen, the concurrent lack of Type II collagen expression at 4 weeks may reflect synthesis of a Type I collagen-rich fibrous tissue in the carrier-only and rhBMP-2/carrier defects in response to inflammation from surgical trauma. Osteocalcin levels peak between 1 to 4 weeks in uninfected fracture models [23, 26, 36, 37, 49] , agreeing with our finding of peak expression at 2 weeks for the carrier/rhBMP-2 group. We observed increased osteocalcin mRNA in the rhBMP-2 plus infection condition versus infection alone at 4 weeks, consistent with our hypothesis. Additionally, we found greater BMP Type II receptor message expression in the infected groups after rhBMP-2 treatment. BMP Type II receptor mRNA expression has not been previously examined in a critical defect model with exogenous rhBMP-2 but has been reported to exhibit BMP-2 dose-dependent upregulation in vitro [30, 38] . In response to osteoblastic signaling pathways induced by fracture [20-22, 28, 29, 39, 43] , BMP Type II receptor is known to colocalize with the BMP Type I receptor [27, 31, 44] , forming a heterodimeric complex with endogenous BMP-2 [40, 48] . Thus, it is not surprising the expression profile observed shows a similar pattern as that reported for the Type IA BMP receptor, which peaked at low levels [52] at 1 week in a noninfected defect [37] , consistent with our carrier-only controls.
We were able to demonstrate earlier peak expression in the setting of infection for the BMP Type II receptor, confirming our second hypothesis for this gene in particular. Both infected groups followed markedly different patterns of BMP Type II receptor expression than the noninfected groups. Because there is little in vivo experimental data with which to compare our results, the novel trends observed in the context of infection may help clarify the role of BMP Type II receptor action with rhBMP-2. The other genes showed no evidence of accelerated expression, but rhBMP-2 did maintain upregulation of Type I collagen mRNA out to 4 weeks. The Type II collagen message peaked at 1 week in all conditions; this was previously observed [9, 26, 37, 45] . Since osteocalcin mRNA is only expressed during the later stages of fracture healing [3, 26, 33, 34] , our data indicate bacterial infection delayed the BMP-promoted matrix mineralization. It is possible early proliferation of bacteria in the infected defect may have inhibited neovascularization [14] , delaying osteogenesis. Local hypoxia may also contribute since decreased oxygen tension reduces osteoblastic differentiation and expression of osteocalcin mRNA in vitro [50] . The application of a BMP may encourage neovascularization of the site [11, 12, 41] and the differentiation of fibroblastic and angiogenic elements within the defect [24] .
We have shown increased expression for an extended period of time of four genes important for fracture healing within an infected critical defect when stimulated by rhBMP-2. Previous studies suggest BMP treatment stimulates new bone formation in an infected critical defect [2, [4] [5] [6] [7] 34] , but this osseous response is delayed. Our data suggest callus formation differs in a critical defect, depending on BMP treatment, and this differential bone growth is associated with an increased expression of genes involved in fracture healing. It appears the inhibitory effects of infection could be partially overcome with rhBMP-2 application in appropriate clinical settings.
Appendix 1

Detailed Description of Gene Expression Methodologies
RNA Isolation and cDNA Synthesis
Frozen samples were weighed and processed for total RNA isolation by freezer mill pulverization under liquid nitrogen (6750 Freezer Mill; SPEX SamplePrep LLC, Metuchen, NJ) with guanidine isothiocyanate (TRIZOL 1 ; Life Technologies, Grand Island, NY) and subsequent phenol extraction using a previously described method [8] . The RNA pellet formed was dissolved in approximately 40 lL Tris-EDTA (TE) (pH 7.25) and stored at -808C. RNA purity was periodically assessed visually by 1.5% agarose gel electrophoresis, revealing both 18S and 28S bands. Total RNA concentration was obtained through ultraviolet spectrophotometry in TE solution. The RNA was then diluted to 1 lg/lL using nuclease-free H 2 O. First strand cDNA synthesis was done by reverse transcription using 1 lg/lL total RNA and oligo p (dT) 15 primers (Roche Molecular Biochemicals, Basel, Switzerland).
Primer Design and Real-time Quantitative PCR Optimization
Forward (F) and reverse (R) primers were designed for bactin, Types I and II collagen, osteocalcin, and BMP Type II receptor with MacVector software (Accelrys Software, Inc, San Diego, CA) using established cDNA sequences for Rattus norvegicus. The primers were synthesized by the Biomedical Genomics Center at the University of Minnesota (Minneapolis, MN). Their inherent characteristics are shown (Appendix Table 1 ).
The optimal F:R ratio for each primer set was determined by testing 5:1, 3:1, 1:1, 1:3, and 1:5 ratios on a control cDNA sample. Real-time annealing time and temperature, magnesium concentration, and amplification efficiency were independently determined using this sample. The control cDNA sample was further used as an internal calibrator for each real-time run to control for differences in reverse transcription and amplification of the cDNA, demonstrating an interrun variability from 1% to 6% among all five genes. The passive reference dye was used to account for minute interwell differences due to potential pipetting errors. No-template controls were also used to evaluate product specificity and monitor dimerization in conjunction with the dissociation curve. Magnesium chloride concentration was tested at 3, 4, and 5 mmol/L of the total 25-lL reaction volume, eliciting the lowest cycle threshold fluorescence value (Ct) at the default amount of 2.5 mmol/L. The amplification efficiencies for all genes were determined to be approximately equal and were 97.6% or greater using a 10-fold dilution series over 4 orders of magnitude. Comparable efficiencies close to 1.0 validated the use of the primer sets and ratios.
Real-time Comparative PCR
Real-time comparative quantitative PCR was performed using the Mx3000P TM Quantitative PCR System thermal cycler and MxPro TM software (Stratagene Corp, La Jolla, CA). SYBR 1 Green dye detection (Invitrogen, Carlsbad, CA) with an accompanying dissociation curve was used to detect the comparative amounts of b-actin, Type I collagen, osteocalcin, Type II collagen, and BMP Type II receptor mRNAs in samples from the newly mineralized callus harvested from the femoral defects. b-Actin served as the comparative normalizer gene. Samples were analyzed in Appendix triplicate with a final reaction volume of 25 lL. Master mixes were made for each primer set and included 8.125 lL nuclease-free H 2 O, 12.5 lL SYBR 1 Green dye, 2 lL (400 nmol/L of total reaction) of the appropriate F:R primer ratio, and 0.375 lL 1:500 reference dye as a fluorescence control. The optimal real-time thermocycler conditions were 958C for 15 minutes followed by 40 cycles of 958C for 30 seconds to denature the cDNA, 568C for 45 seconds for annealing, and 728C for 30 seconds for extension. The cycle ended with a dissociation step to examine product quality.
Gene Expression
The Ct expression of each gene was subtracted relative to the Ct of the normalizer b-actin for each animal. The fold change from b-actin was computed using the formula 2 -DCt , and the average fold change was found for the six animals in each treatment/time point [15, 32] .
